603 related articles for article (PubMed ID: 29253163)
1. Prevalence of carbapenem resistance and carbapenemase production among Enterobacteriaceae isolated from urine in the UK: results of the UK infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-UK).
Woodford N; Xu-McCrae L; Mushtaq S; Wu HHT; Ellington MJ; Lancaster O; Davies F; Donaldson H; Rao GG; Verma A; Wareham DW; Ciesielczuk H; Stone GG; Irani PM; Bracher S; Hawkey PM
J Antimicrob Chemother; 2018 Mar; 73(3):698-702. PubMed ID: 29253163
[TBL] [Abstract][Full Text] [Related]
2. Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain.
García-Castillo M; García-Fernández S; Gómez-Gil R; Pitart C; Oviaño M; Gracia-Ahufinger I; Díaz-Regañón J; Tato M; Cantón R;
Int J Antimicrob Agents; 2018 Mar; 51(3):511-515. PubMed ID: 29371104
[TBL] [Abstract][Full Text] [Related]
3. Results of the Italian infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-IT): activity of ceftazidime/avibactam against Enterobacterales isolated from urine.
Giani T; Antonelli A; Sennati S; Di Pilato V; Chiarelli A; Cannatelli A; Gatsch C; Luzzaro F; Spanu T; Stefani S; Rossolini GM
J Antimicrob Chemother; 2020 Apr; 75(4):979-983. PubMed ID: 31958125
[TBL] [Abstract][Full Text] [Related]
4. An agar plate-based modified carbapenem inactivation method (p-mCIM) for detection of carbapenemase-producing Enterobacteriaceae.
Byun JH; Seo Y; Kim D; Kim M; Lee H; Yong D; Lee K; Chong Y
J Microbiol Methods; 2020 Jan; 168():105781. PubMed ID: 31756348
[TBL] [Abstract][Full Text] [Related]
5. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.
Livermore DM; Meunier D; Hopkins KL; Doumith M; Hill R; Pike R; Staves P; Woodford N
J Antimicrob Chemother; 2018 Mar; 73(3):648-657. PubMed ID: 29228202
[TBL] [Abstract][Full Text] [Related]
6.
Huang YS; Chen PY; Chou PC; Wang JT
Microbiol Spectr; 2023 Jun; 11(3):e0056923. PubMed ID: 37154758
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and mechanisms of resistance to carbapenems in Enterobacteriaceae isolates from 24 hospitals in Belgium.
Huang TD; Berhin C; Bogaerts P; Glupczynski Y;
J Antimicrob Chemother; 2013 Aug; 68(8):1832-7. PubMed ID: 23557926
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M
Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam.
De la Calle C; Rodríguez O; Morata L; Marco F; Cardozo C; García-Vidal C; Río AD; Feher C; Pellicé M; Puerta-Alcalde P; Mensa J; Soriano A; Martínez JA
Int J Antimicrob Agents; 2019 Apr; 53(4):520-524. PubMed ID: 30471403
[TBL] [Abstract][Full Text] [Related]
10. Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope.
Avery LM; Nicolau DP
Int J Antimicrob Agents; 2018 Nov; 52(5):688-691. PubMed ID: 30044946
[TBL] [Abstract][Full Text] [Related]
11. Carbapenemase-producing Enterobacteriaceae in South Korea: a report from the National Laboratory Surveillance System.
Yoon EJ; Yang JW; Kim JO; Lee H; Lee KJ; Jeong SH
Future Microbiol; 2018 Jun; 13():771-783. PubMed ID: 29478336
[TBL] [Abstract][Full Text] [Related]
12. Carbapenemase-producing Enterobacteriaceae in the UK: a national study (EuSCAPE-UK) on prevalence, incidence, laboratory detection methods and infection control measures.
Trepanier P; Mallard K; Meunier D; Pike R; Brown D; Ashby JP; Donaldson H; Awad-El-Kariem FM; Balakrishnan I; Cubbon M; Chadwick PR; Doughton M; Doughton R; Hardiman F; Harvey G; Horner C; Lee J; Lewis J; Loughrey A; Manuel R; Parsons H; Perry JD; Vanstone G; White G; Shetty N; Coia J; Wiuff C; Hopkins KL; Woodford N
J Antimicrob Chemother; 2017 Feb; 72(2):596-603. PubMed ID: 27687074
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
[TBL] [Abstract][Full Text] [Related]
14. Nitro-Carba test, a novel and simple chromogenic phenotypic method for rapid screening of carbapenemase-producing Enterobacteriaceae.
Teethaisong Y; Nakouti I; Evans K; Eumkeb G; Hobbs G
J Glob Antimicrob Resist; 2019 Sep; 18():22-25. PubMed ID: 30668995
[TBL] [Abstract][Full Text] [Related]
15. Evaluating NG-Test CARBA 5 Multiplex Immunochromatographic and Cepheid Xpert CARBA-R Assays among Carbapenem-Resistant
Huang YT; Kuo YW; Lee NY; Tien N; Liao CH; Teng LJ; Ko WC; Hsueh PR;
Microbiol Spectr; 2022 Feb; 10(1):e0172821. PubMed ID: 35019772
[TBL] [Abstract][Full Text] [Related]
16. Detection and epidemiology of carbapenemase producing Enterobacteriaceae in the Netherlands in 2013-2014.
Vlek AL; Frentz D; Haenen A; Bootsma HJ; Notermans DW; Frakking FN; de Greeff SC; Leenstra T;
Eur J Clin Microbiol Infect Dis; 2016 Jul; 35(7):1089-96. PubMed ID: 27126332
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of intestinal carriage of carbapenem-resistant Enterobacteriaceae among inpatients at two Iranian university hospitals: first report of co-production of bla
Solgi H; Badmasti F; Aminzadeh Z; Giske CG; Pourahmad M; Vaziri F; Havaei SA; Shahcheraghi F
Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2127-2135. PubMed ID: 28639165
[TBL] [Abstract][Full Text] [Related]
18. Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenemase-Producing Enterobacteriaceae.
Marimuthu K; Ng OT; Cherng BPZ; Fong RKC; Pada SK; De PP; Ooi ST; Smitasin N; Thoon KC; Krishnan PU; Ang MLT; Chan DSG; Kwa ALH; Deepak RN; Chan YK; Chan YFZ; Huan X; Zaw Linn K; Tee NWS; Tan TY; Koh TH; Lin RTP; Hsu LY; Sengupta S; Paterson DL; Perencevich E; Harbarth S; Teo J; Venkatachalam I;
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383670
[TBL] [Abstract][Full Text] [Related]
19. Activity of BAL30072 alone or combined with β-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters.
Mushtaq S; Woodford N; Hope R; Adkin R; Livermore DM
J Antimicrob Chemother; 2013 Jul; 68(7):1601-8. PubMed ID: 23449829
[TBL] [Abstract][Full Text] [Related]
20. Meropenem-Vaborbactam Activity against Carbapenem-Resistant
Castanheira M; Doyle TB; Kantro V; Mendes RE; Shortridge D
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
